Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second ...
The Manila Times9h
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
Acrivon has developed its AP3 Interactome, a proprietary, computational analytics platform driven by Generative ...